The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 02, 2025
Filed:
Oct. 10, 2019
Applicant:
Nantomics, Llc, Culver City, CA (US);
Inventors:
John Zachary Sanborn, Culver City, CA (US);
Andrew Nguyen, Culver City, CA (US);
Assignee:
Nantomics, LLC, Culver City, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 40/42 (2025.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56977 (2013.01); A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 39/0011 (2013.01); A61K 39/39558 (2013.01); A61K 40/4202 (2025.01); C12Q 1/6886 (2013.01); G01N 33/57492 (2013.01); G01N 33/6878 (2013.01); A61K 2039/523 (2013.01); A61K 2039/5256 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); G01N 2570/00 (2013.01);
Abstract
Effectiveness of a neoepitope-based immunotherapeutic composition against a tumor can be increased by predicting the surface presentation of the neoepitope bound to the HLA molecule of the tumor cell. Surface presentation levels of neoepitopes can be predicted by identifying any changes in omics data of the tumor cell that may affect the expression or surface trafficking of the HLA molecule and that may affect binding affinities of neoepitopes to the HLA molecule.